Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Introduces TruSeq® Amplicon - Cancer Panel for MiSeq® System

Published: Monday, March 12, 2012
Last Updated: Monday, March 12, 2012
Bookmark and Share
Allows researchers to rapidly detect hundreds of cancer mutations.

Illumina has introduced the TruSeq Amplicon - Cancer Panel, a highly multiplexed panel that will allow researchers to accurately sequence hundreds of the most relevant cancer loci, even in difficult samples such as formalin-fixed, paraffin embedded (FFPE) tumor samples.

With the ability to detect mutations below 5% frequency, the TruSeq Amplicon assay provides the highest quality data across many samples, all in one experiment.

“The TruSeq Amplicon - Cancer Panel is an important advancement for clinical researchers, enabling them to conduct in a matter of days cancer studies that were previously impractical,” said Christian Henry, Senior Vice President and General Manager of Illumina’s Genomics Solutions Business.

Henry continued, “Combined with the accuracy, speed, and ease of use of the MiSeq personal sequencer, this powerful new solution will help unlock millions of FFPE samples as our customers seek to elucidate the biological complexity of cancer.”

In a single experiment, researchers can access the most content on any commercially available amplicon cancer panel, including key genes that are associated with drug response and sensitivity.

Mutations in such genes are linked to many cancers, including melanoma, lung cancer, ovarian cancer, and colorectal cancer.

The TruSeq Amplicon - Cancer Panel also delivers confidence and simplicity with up front FFPE sample quality control, built-in assay controls, and on-instrument automated analysis for variant calling.

“In tests on real tumor samples, we confirmed all previously detected mutations,” said Dr. Andrew Fellowes, of the Department of Pathology at the Peter MacCallum Cancer Centre in Melbourne, Australia.

Dr. Fellowes continued, “This targeted panel on the MiSeq system will enable us to profile tumor samples for a wider range of mutations and with greater speed and sensitivity than is possible with our current technology.”

The MiSeq system utilizes TruSeq, the industry’s most trusted and accurate sequencing chemistry, powering over 2,300 scientific publications.

TruSeq targeted resequencing products offer complete, end-to-end, cost effective solutions for any study design, with pre-kitted reagents, simple workflows and validated multliplexed sample processing.

Intended for research use only, the TruSeq Amplicon - Cancer Panel is complementary to the strategy of Illumina's recently created Translational and Consumer Genomics (TCG) business, which is focused on delivering genomic solutions to CLIA labs.

The TCG has begun to partner with clinical thought leaders to develop targeted resequencing panels for both MiSeq and HiSeq® systems, building on the current TruSeq Amplicon and TruSeq Enrichment assays, including extensions of the content that comprises the TruSeq Amplicon - Cancer Panel.

The TruSeq Amplicon - Cancer Panel is now available for order and will begin shipping in April 2012.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Files Patent Infringement Suit in the UK Against Premaitha Health
Suit is filed for Infringement of NIPT Patents.
Monday, March 16, 2015
Illumina Revenues Jump 35 Percent
Company’s Third Quarter 2014 Results Announced.
Tuesday, October 21, 2014
Illumina's HiSeq X Ten Sequencing Technology for Population Studies
Next-generation sequencing technologies to be implemented at new High-Throughput Genomics Center for the MENA region.
Tuesday, July 22, 2014
Novogene Acquires an Illumina HiSeq X Ten Sequencing System
First-in-China deal Iincreases Novogene's investment in Illumina's Next-Generation Sequencing technology.
Thursday, February 13, 2014
Illumina Announces Recipients of Agricultural Greater Good Initiative Grants
Expanded program focuses on improving food security and furthering agricultural sustainability.
Wednesday, January 16, 2013
Illumina Awarded FDA Contract for NGS Technology to Identify Foodborne Pathogens
Agency selects MiSeq® system for program to explore NGS as mechanism to enhance food safety.
Wednesday, September 19, 2012
The Broad Institute Joins the Illumina Genome Network
Partnership expands the network’s capabilities to enable sequencing of previously inaccessible samples.
Tuesday, June 05, 2012
Cold Spring Harbor Laboratory Joins the Illumina Genome Network
Partnership expands access to large-scale whole genome sequencing.
Monday, May 28, 2012
Illumina Comments on Roche’s Unsolicited Tender Offer Extension
Roche to acquire all outstanding shares of Illumina for $44.50 in cash per common share.
Monday, February 27, 2012
Illumina's Board Unanimously Rejects Roche's Unsolicited Tender Offer
Urges stockholders not to tender their shares, company considers offer inadequate.
Wednesday, February 08, 2012
BCCA Joins the Illumina Genome Network
Network expansion making affordable, high quality whole human genome sequencing services accessible world-wide.
Friday, January 20, 2012
Illumina Appoints Marc Stapley as Senior Vice President and CFO
Stapley brings multi-national experience in high-growth and mature industries.
Thursday, January 05, 2012
Illumina and University of Oxford to Sequence 500 Whole Human Genomes for Rare Disease Research
Opportunity to bring personalized medicine to the forefront of healthcare.
Tuesday, January 03, 2012
Illumina Reports Financial Results for Second Quarter 2011
Revenue of $287.5 million, a 36% increase over the $212.0 million reported in the second quarter of 2010.
Wednesday, July 27, 2011
University of Washington Department of Genome Sciences Joins Illumina Genome Network
Network makes affordable, high-quality whole human genome sequencing services more accessible to life sciences researchers.
Friday, July 01, 2011
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be pair with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Sensor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!